Table 2. Follow-up of 11 patients with... | American Society of Hematology

Table 2.

Follow-up of 11 patients with TTP treated with rituximab

	3-mo follow-up			6-mo follow-up
Patient no.	ADAMTS13 activity in plasma, %	Inhibitory activity to ADAMTS13 in plasma	ADAMTS13 activity in plasma, %	Inhibitory activity to ADAMTS13 in plasma	ADAMTS13 activity in plasma, %	Inhibitory activity to ADAMTS13 in plasma
1	< 5	Positive	18	Negative	26	Negative
2	< 5	Negative	27	Negative	47	Negative
3	< 5	Positive	33	Negative	38	Negative
4	35	Negative	35	Negative	NA	NA
5	56	Negative	54	Negative	32	Negative
6	18	Negative	21	Negative	10^*	Negative^*
7	33	Negative	56	Negative	46	Positive (weak)
8	< 5	Positive	75	Negative	NA	NA
9	46	Negative	29	Negative	18^*	Negative^*
10	24	Negative	32	Negative	18	Negative
11	67	Negative	65	Negative	29	Negative

	3-mo follow-up			6-mo follow-up
Patient no.	ADAMTS13 activity in plasma, %	Inhibitory activity to ADAMTS13 in plasma	ADAMTS13 activity in plasma, %	Inhibitory activity to ADAMTS13 in plasma	ADAMTS13 activity in plasma, %	Inhibitory activity to ADAMTS13 in plasma
1	< 5	Positive	18	Negative	26	Negative
2	< 5	Negative	27	Negative	47	Negative
3	< 5	Positive	33	Negative	38	Negative
4	35	Negative	35	Negative	NA	NA
5	56	Negative	54	Negative	32	Negative
6	18	Negative	21	Negative	10^*	Negative^*
7	33	Negative	56	Negative	46	Positive (weak)
8	< 5	Positive	75	Negative	NA	NA
9	46	Negative	29	Negative	18^*	Negative^*
10	24	Negative	32	Negative	18	Negative
11	67	Negative	65	Negative	29	Negative

Patients 1 to 6 received curative rituximab treatment during an acute refractory episode of TTP, and patients 7 to 11 were included during clinical remission for prophylactic rituximab treatment.

NA indicates not available.

Data at 11 months of follow-up

View Large

This Feature Is Available To Subscribers Only